Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53

Toxicology and Applied Pharmacology

Volumn 273, Issue 1, 2013, Pages 110-120

  Wang, Jing Ping ^a   Lin, Kai Han ^a   Liu, Chun Yen ^a   Yu, Ya Chu ^a   Wu, Pei Tsun ^a   Chiu, Chien Chih ^b   Su, Chun Li ^a   Chen, Kwun Min ^a   Fang, Kang ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Human non small cell lung cancer cells; P53; Teroxirone

Indexed keywords

CASPASE 3 INHIBITOR; DNA; P21 ACTIVATED KINASE; PROCASPASE 3; PROTEIN P53; SMALL INTERFERING RNA; TEROXIRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR XENOGRAFT;

APOPTOSIS; HUMAN NON-SMALL-CELL-LUNG-CANCER CELLS; P53; TEROXIRONE;

ANIMALS; ANNEXIN A5; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMET ASSAY; CYTOCHROMES C; DNA DAMAGE; DOWN-REGULATION; HUMANS; MICE; MICE, NUDE; RNA, SMALL INTERFERING; TRIAZINES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884705953     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.08.007     Document Type: Article

References (33)

1. Ames M.M., Kovach J.S., Rubin J. Pharmacological characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans. Cancer Res. 1984, 44:4151-4156.
2. An J., Gao Y., Wang J., Zhu Q., Ma Y., Wu J., Sun J., Tang Y. Flavokawain B induces apoptosis of non-small cell lung cancer H460 cells via Bax-initiated mitochondrial and JNK pathway. Biotechnol. Lett. 2012, 34:1781-1788.
3. Atassi G., Spreafico F., Dumont P., Nayer P., Klastersky J. Antitumoral effect in mice of a new triepoxyde derivative: 1,3,5-triglycidyl-s-triazinetrione (NSC 296934). Eur. J. Cancer 1980, 16:1561-1567.
4. Atassi G., Dumont P., Fisher U., Zeidler M., Budnowski M. Preclinical evaluation of the anti tumour activity of new epoxide derivatives. Cancer Treat. Rev. 1984, 11(Suppl. A):99-110.
5. Boehme K.A., Kulikov R., Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7785-7790.
6. Chiu C.C., Lin C.H., Fang K. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 2005, 10:643-650.
7. Christophorou M.A. Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 2005, 37:718-726.
8. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443:214-217.
9. Crespo R., Villaverde M.L., Girotti J.R., Güerci A., Juárez M.P., de Bravo M.G. Cytotoxic and genotoxic effects of defence secretion of Ulomoides dermestoides on A549 cells. J. Ethnopharmacol. 2011, 136:204-209.
10. Dash B.C., El-Deiry W.S. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol. Cell. Biol. 2005, 25:3364-3387.
11. Dombernowsky P., Lund B., Hansen H.H. Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934). Cancer Chemother. Pharmacol. 1983, 11:59-61.
12. Fischer H., Zeidler U., Budnowski M., Atassi G., Dumont P., Venditti J., Yoder O.C. Investigation of the antitumor activity of new epoxide derivatives. Part I: s-triazinetrione derivatives. Arzneim. Forsch. 1984, 34:543-547.
13. Gualtieri M., Rigamonti L., Galeotti V., Camatini M. Toxicity of tire debris extracts on human lung cell line A549. Toxicol. In Vitro 2005, 19:1001-1008.
14. Hsu Y.L., Kuo P.L., Lin C.C. The proliferative inhibition and apoptotic mechanism of saikosaponin D in human non-small cell lung cancer A549 cells. Life Sci. 2004, 75:1231-1242.
15. Khan M., Zheng B., Yi F., Rasul A., Gu Z., Li T., Gao H., Qazi J.I., Yang H., Ma T. Pseudolaric acid B induces caspase-dependent and caspase-independent apoptosis in u87 glioblastoma cells. Evidence-based Compl. Alt. Med.: eCAM 2012 2012, 957568.
16. Lim S.W., Ting K.N., Bradshaw T.D., Zeenathul N.A., Wiart C., Khoo T.J., Lim K.H., Loh H.S. Acalypha wilkesiana extracts induce apoptosis by causing single strand and double strand DNA breaks. J. Ethnopharmacol. 2011, 138:616-623.
17. Ling S., Lin W.-C. EDD inhibits ATM-mediated phosphorylation of p53. J. Biol. Chem. 2011, 286:14972-14982.
18. Meek D.W. Tumour suppression by p53: a role for the DNA damage response?. Nat. Rev. Cancer 2009, 9:714-723.
19. Neidhart J.A., Derocher D., Grever M.R., Kraut E.H., Malspeis L. Phase I trial of teroxirone. Cancer Treat. Rep. 1984, 68:1115-1119.
20. Nicaise C., Rozencweig M., Crespeigne N., Dodion P., Gerard B., Lambert M., Decoster G., Kenis Y. Phase I study of triglycidylurazol given on a 5-day i.v. schedule. Cancer Treat. Rep. 1986, 70:599-603.
21. Offer H., Erez N., Zurer I., Tang X., Milyavsky M., Goldfinger N., Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis 2002, 23:1025-1032.
22. Oliver P.G., LoBuglio A.F., Zinn K.R., Kim H., Nan L., Zhou T., Wang W., Buchsbaum D.J. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin. Cancer Res. 2008, 14:2180-2189.
23. Petty T.J., Emamzadah S., Costantino L., Petkova I., Stavridi E.S., Saven J.G., Vauthey E., Halazonetis T.D. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J. 2011, 30:2067-2076.
24. Piccart M., Rozencweig M., Dodion P., Cumps E., Crespeigne N., Makaroff O., Atassi G., Kisner D., Kenis Y. Phase I clinical trial with alpha 1,3,5-triglycidyl-s-triazinetrione (NSC-296934). Eur. J. Cancer Clin. Oncol. 1981, 17:1263-1266.
25. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
26. Rubin J., Kovach J.S., Ames M.M., Moertel C.G., Creagan E.T., O'Connell M.J. Phase I study of two schedules of teroxirone. Cancer Treat. Rep. 1987, 71:489-492.
27. Siddiqui-Jain A., Bliesath J., Macalino D., Omori M., Huser N., Streiner N., Ho C.B., Anderes K., Proffitt C., O'Brien S.E., Lim J.K.C., Von Hoff D.D., Ryckman D.M., Rice W.G., Drygin D. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol. Cancer Ther. 2012, 11:994-1005.
28. Simbulan-Rosenthal C.M., Rosenthal D.S., Iyer S., Boulares H., Smulson M.E. Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Mol. Cell. Biochem. 1999, 193:137-148.
29. Spreafico F., Atassi G., Filippeschi S., Malfiore C., Noseda S., Boschetti D. A characterization of the activity of alpha-1,3,5-triglycidyl-s-triazinetrione, a novel antineoplastic compound. Cancer Chemother. Pharmacol. 1980, 5:103-108.
30. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
31. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6:909-923.
32. Weigel T.L., Lotze M.T., Kim P.K., Amoscato A.A., Luketich J.D., Odoux C. Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J. Thorac. Cardiovasc. Surg. 2000, 119:795-803.
33. Yan K.H., Yao C.J., Chang H.Y., Lai G.M., Cheng A.L., Chuang S.E. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol. Carcinog. 2010, 49:235-246.